logo

For the Inventor, By the Inventor

Kanagawa, Japan

Tohru Miyazaki

This inventor holds 15 USPTO granted patents and 5 published patent applications and 7 EPO patents, primarily in Heterocyclic Compounds. Top assignee: Takeda Pharmaceutical Company Limited. Active years: 2019-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Tohru Miyazaki. Retrieved from https://idiyas.com/inventor/tohru-miyazaki-klfno88k

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank
USPTO Granted Patents = 15 

% Patents Active = 93.3

 

Average Co-Inventor Count = 14.8

ph-index = 4

Forward Citations = 50(Granted Patents)


Company Filing History:

goldMedal15 out of 1,229 
 
Takeda Pharmaceutical Company Limited
 patents

Years Active: 2019-2026

Loading Chart...
Loading Chart...
Areas of Expertise:
Heterocyclic Compound
Sleepiness Treatment
Cataplexy
HDAC6 Inhibitor
Sulfonamide Derivatives
Pharmaceutical Applications
Chemical Compounds
Drug Development
Therapeutic Uses
15 patents (USPTO):Explore Patents
1. 12662453 - Heterocyclic compound and use thereof (2026-06-23),
2. 12421188 - Heterocyclic compound and use thereof (2025-09-23),
3. 12415782 - Heterocyclic compound and use thereof (2025-09-16),
4. 12404237 - Method of treating excessive sleepiness and/or cataplexy using n-{2-(([1,1'-biphenyl]-3-yl)methyl)pyrrolidin-3-yl}sulfonamide derivatives (2025-09-02),
5. 12091410 - Heterocyclic compound (2024-09-17),
6. 12084436 - Heterocyclic compound (2024-09-10),
7. 12077522 - Heterocyclic compound and application thereof (2024-09-03),
8. 12071434 - Heterocyclic compound (2024-08-27),
9. 11655241 - Heterocyclic compound and use thereof (2023-05-23),
10. 11440883 - Heterocyclic compound and use thereof (2022-09-13),
11. 11319286 - Heterocyclic compound and application thereof (2022-05-03),
12. 11028048 - Heterocyclic compound and use thereof (2021-06-08),
13. 10584097 - Heterocyclic compound and use thereof (2020-03-10),
14. 10435399 - HDAC6 inhibitory heterocyclic compound (2019-10-08),
15. 10428023 - Heterocyclic compound and use thereof (2019-10-01),

Title: Tohru Miyazaki: Innovator in Heterocyclic Compounds

Introduction

Tohru Miyazaki is a prominent inventor based in Kanagawa, Japan. He has made significant contributions to the field of pharmaceuticals, particularly in the development of heterocyclic compounds. With a total of 14 patents to his name, Miyazaki's work has the potential to impact the treatment of various medical conditions.

Latest Patents

Miyazaki's latest patents focus on heterocyclic compounds that exhibit orexin type 2 receptor agonist activity. These compounds are particularly useful as agents for the prophylaxis or treatment of narcolepsy. The innovative compounds he has developed are represented by specific formulas, which are detailed in the patent specifications.

Career Highlights

Tohru Miyazaki is currently associated with Takeda Pharmaceutical Company Limited, where he continues to advance his research and development efforts. His work has garnered attention in the pharmaceutical industry, contributing to the understanding and treatment of sleep disorders.

Collaborations

Miyazaki collaborates with notable colleagues, including Yuichi Kajita and Yuhei Miyanohana. These partnerships enhance the research and development process, fostering innovation in the field.

Conclusion

Tohru Miyazaki is a key figure in the development of heterocyclic compounds, with a focus on improving treatments for narcolepsy. His contributions to the pharmaceutical industry are noteworthy and continue to influence medical research.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…